Clairity Breast analyzes subtle patterns in screening mammograms linked to future breast cancer risk, generating a validated five-year risk score. This score is seamlessly integra ...

BI-RADS stands for Breast Imaging Reporting and Data System. It is an assessment tool used to rate the results of a mammogram test. It also assesses your overall breast tissue density. With more ...

The dynamic risk prediction model using mammogram images from the previous 3 years gives a 5-year AUC of 0.80 (95% CI, 0.78 to 0.83) that is robust across Black and White women, age, and BI-RADS ...

A BI-RADS score of 3, or "probably benign" means that there is something of uncertain significance on your mammogram, but that it is most likely not cancer. A follow-up mammogram may be ...

Mammography facilities are now required to provide all patients who receive a mammogram with 1 of 2 federal breast density notification statements—“not dense” or “dense”—effective ...

Of the 559 examinations, 95 were graded at BI-RADS 3-5 and flagged for further work-up. Biopsies were obtained for 71 of these 95.

Specifically, the combination increased sensitivity for detecting BI-RADS 4 or higher lesions by 25% and improved specificity for BI-RADS 3 lesions by 8%, compared to mammography alone.

Adding SoftVue UST to screening mammography led to astatistically significant 25% improvement in sensitivity for breast cancer detection of BI-RADS 4 or higher lesions compared with mammography alone.

Approval was based on data from a published prospective study of 216 women who had BI-RADS 3, 4, or 5 findings on mammography. The Food and Drug Administration (FDA) has expanded the approval of ...